Protocol Ledger

NCT07626411 · Phase III · RECRUITING

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Interventional Phase III clinical trial protocol NCT07626411 sponsored by Regeneron Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-10 Enrollment: 15,364 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07626411
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)15,364 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07626411
Protocol FieldVerified Registry Value
NCT IdentifierNCT07626411
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment15,364 participants (ESTIMATED)
Registered Start Date2026-08-10
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI